martes, 16 de marzo de 2010

Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. -


GUIDELINE TITLE
Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults.

BIBLIOGRAPHIC SOURCE(S)
National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Sep. 59 p. (Clinical guideline; no. 72).


GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory information has been released.

July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

abrir aquí para acceder al documento NGC AHRQ completo:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=14325&nbr=&string=

No hay comentarios:

Publicar un comentario